4种生物学因子对局部晚期乳腺癌新辅助化疗疗效评估的价值

doi:10.16098/j.issn.0529-1356.2019.03.011

摘要/Abstract

摘要：

目的探讨p53、ki67、nm23、表皮生长因子受体(EGFR)在局部晚期乳腺癌新辅助化疗疗效评估中的价值。方法选取2013年1月1日~2018年3月31日我院收治的局部晚期乳腺癌患者98例，检测新辅助化疗前后p53、ki67、nm23、EGFR的变化及其与临床疗效的关系。结果化疗后的p53、ki67、EGFR阳性表达均较化疗前降低，nm23阳性表达均较化疗前升高，差异均有统计学意义（P<0.05）。p53阳性者的有效率低于阴性者，差异有统计学意义（P<0.05）；ki67、nm23阳性者的有效率均高于阴性者，差异均有统计学意义（P<0.05）；EGFR阳性者与阴性者的有效率差异无统计学意义（P>0.05）。结论新辅助化疗能够显著改善局部晚期乳腺癌患者生物学因子p53、ki67、EGFR、nm23的表达，同时p53、ki67、nm23对评估化疗疗效具有一定价值。

关键词: 乳腺癌, p53, ki67, nm23, 表皮生长因子受体, 新辅助化疗, 人

Abstract:

To explore the value of p53, Ki67, nm23 and epidermal growth factor receptor (EGFR) in the evaluation of the efficacy of neoadjuvant chemotherapy for locally advanced breast cancer. Methods From January 1, 2013 to March 31, 2018, 98 cases of locally advanced breast cancer in our hospital were selected as the research subjects. The changes of p53, Ki67, nm23 and EGFR before and after neoadjuvant chemotherapy and their relationship with clinical efficacy were detected. Results The positive expression of p53, Ki67 and EGFR after chemotherapy were all lower than those before chemotherapy, and the positive expression of nm23 was higher than that before chemotherapy, the difference was statistically significant (P<0.05). The effective rate of p53 positive was lower than that of the negative ones, and the difference was statistically significant (P<0.05). The effective rates of Ki67 and nm23 positive were higher than that of negative ones, and the difference was statistically significant (P<0.05). There was no statistical difference in effective rate between the positive EGFR and negative ones (P>0.05). Conclusion Neoadjuvant chemotherapy can significantly improve the expression of biological factors p53, Ki67, EGFR and nm23 in locally advanced breast cancer patients, and p53, Ki67 and nm23 have certain value in evaluating the curative effect of chemotherapy.

Key words: Breast cancer, p53, ki67, nm2, Epidermal growth factor receptor, Neoadjuvant chemotherapy, Human

顾蓓郭斌石国建李惠华张洁. 4种生物学因子对局部晚期乳腺癌新辅助化疗疗效评估的价值[J]. 解剖学报, 2019, 50(3): 329-333.

GU Bei GUO Bin, SHI Guo-jian LI Hui-hua ZHANG Jie. Value of four biological factors in the evaluation of neoadjuvant chemotherapy for locally advanced breast cancer[J]. Acta Anatomica Sinica, 2019, 50(3): 329-333.

参考文献

［1］ Yao LSh, Yuan YL, Li Y, et al. Construction of eukaryotic expression vector of PinX1 gene and its expression in breast cancer cells［J］. Practical Geriatrics, 2015,29(12):1000-1003. (in Chinese)

姚乐申，袁毅路，李燕, 等. PinX1基因的真核表达载体构建及其在乳腺癌细胞中的表达［J］. 实用老年医学,2015,29(12):1000-1003.

［2］ Hu GW, Wang JD, Zhao ChY. Effect of acupuncture on the first WBC reduction after chemotherapy for breast cancer［J］. Beijing Traditional Chinese Medicinem, 2015,35(8):777-779. (in Chinese)

胡高武，王建东，赵春英. 针刺治疗对乳癌化疗后首次WBC减少症的影响［J］. 北京中医药,2015,35(8):777-779.

［3］ Broglio KR, Quintana M, Foster M, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-Positive breast cancer with longterm outcomes: a meta-analysis［J］. JAMA Oncol,2016,2(6):751-760.

［4］ Li Z, Heng J, Yan J, et al. Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients［J］. Breast Cancer Res Treat,2016,160(2):371-383.

［5］ Leo F, Bartels S, Magel L, et al. Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer［J］. Virchows Arch,2016,469(2):191-201.

［6］ Zhang ChL, Li H, Li JP. Expression of p53, Ki67, EGFR, Nm23 in breast cancer and their correlations with clinical prognosis ［J］. Hainan Medical Journal,2014,25(1):15-17. (in Chinese)

张朝林，李宏，李金平. p53、Ki67、EGFR、Nm23在乳腺癌组织中的表达及临床意义［J］. 海南医学,2014,25(1):15-17.

［7］ Zhang L, Varma NR, Gang ZZ, et al. Targeting triple negative breast cancer with a small-sized paramagnetic nanoparticle［J］. J Nanomed Nanotechnol,2016,7(5):4172-4180.

［8］ Chen AX, Yu Y, Meng R, et al. he predictive value of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant chemotherapy［J］. Chinese Journal of Clinical Oncology, 2017,44(23):1184-1188. (in Chinese)

陈翱翔，余岳，孟然，等. 肿瘤浸润淋巴细胞比例对乳腺癌新辅助化疗疗效的预测作用［J］. 中国肿瘤临床,2017,44(23):1184-1188.

［9］ Yang LX. Clinical efficacy of paclitaxel and platinum in patients with advanced breast cancer and their effects on HER-2 and EGFR［J］. Guide of China Medicine, 2017,15(31):129-130. (in Chinese)

杨丽娴. 乳腺癌晚期患者应用紫杉醇与铂类的临床治疗效果及对HER-2、EGFR的影响研究［J］. 中国医药指南,2017,15(31):129-130.

［10］Yu HY, Li WP, Gao HY, et al. Relationship between the pathological assessment levels of neoadjuvant chemotherapy and the expressions of Ki67 and P53 in breast cancer. ［J］. Chinese Journal of Breast Disease(Electronic Version), 2011,05(3):297-305. (in Chinese)

余海云，李文萍，郜红艺，等. 新辅助化疗疗效与乳腺癌Ki67、P53表达的关系［J］. 中华乳腺病杂志（电子版）,2011,05(3):297-305.

［11］Yang Y, Wei ShZh, Du YX, et al. Expression of p53,Ki-67 and PCNA in esophageal squamous cell carcinoma and correlation with radiotherapy effect and prognosis［J］. Journal of Southeast University(Medical Science Edition), 2017,36(2):155-161. (in Chinese)

杨艳，韦淑贞，杜云翔，等. p53、Ki-67、PCNA的表达与食管鳞癌放疗近期疗效及预后的关系［J］. 东南大学学报（医学版）,2017,36(2):155-161. 

［12］ Wang L, Yu X, Li J, et al. Prognostic significance of p53 expression in patients with esophageal cancer: a metaanalysis［J］. BMC Cancer,2016,16:373.

［13］Cui HB, Ge HE，Bai XY, et al. Application of the predictors EGFR, HER2, Ki-67 and P53 on neoadjuvant chemotherapy in patients with advanced gastric cancer［J］. China Medical Herald, 2014,11(2):35-38. (in Chinese)

崔海滨，葛怀娥，白希永，等. EGFR、HER2、Ki-67、P53在进展期胃癌新辅助化疗疗效预测中的应用［J］. 中国医药导报,2014,11(2):35-38.

［14］Wang HM, Zhang H, Zhang JX. Effect of neoadjuvant chemotherapy on expression of ER PR P53 c-erb-B-2 Ki-67 in breast cancer patients［J］. Anhui Medical Journal, 2014,35(6):724-726. (in Chinese)

王红梅，张晖，张京雪. 新辅助化疗对乳腺癌患者ER PR P53 c-erb-B-2 Ki-67表达的影响［J］. 安徽医学,2014,35(6):724-726.

［15］Ning DB, Zhao YZh, Qi HH. Expression and significance of VEGF and nm23 in primary breast cancer and lymph node metastases［J］. Shandong Medical Journal, 2014,54(35):16-18. (in Chinese)

宁殿宾，赵玉哲，祁红辉. 乳腺癌原发灶和淋巴结转移灶中VEGF、nm23的表达变化及意义［J］. 山东医药,2014,54(35):16-18.

［16］Chen J. Expression of human epidermal growth factor receptor-2, tumor suppressor gene, estrogen receptor and progesterone receptor in elderly women with breast cancer and their clinical treatment［J］. Chinese Journal of Gerontology, 2016,36(9):2181-2183. (in Chinese)

陈军. 老年女性乳腺癌患者人表皮生长因子受体-2、抑癌基因、雌激素受体和孕激素受体表达情况及临床治疗［J］. 中国老年学杂志,2016,36(9):2181-2183.

［17］Wang XY, Zhang WW, Shi XJ, et al. Expressions of VEGF,EGFR and Smad4 in breast cancer tissue and their relationship with lymphatic metastasis［J］. International Journal of Laboratory Medicine,2017,38(23):3300-3302. (in Chinese)

王晓英，张卫卫，施先君，等. 乳腺癌组织中VEGF、EGFR和Smad4的表达及其与淋巴结转移的关系分析［J］. 国际检验医学杂志,2017,38(23):3300-3302.

[1]	刘晓丽许琳吴爱雪闻彩云李如画吴安婷陈黛茜陈成春. 多发性硬化和视神经脊髓炎的脑灰质结构分析 [J]. 解剖学报, 2024, 55(1): 17-24.
[2]	白贺滕野冯蕾孟海伟汤煜春刘树伟. 基于空间域与频域特征自适应融合和类间边界区域增强的三维海马分割[J]. 解剖学报, 2024, 55(1): 73-81.
[3]	尹诗琴杨思艺王锐涵游贵宣杨迎秋张磊. 基于CT平扫下胫腓联合腓骨切迹分型及其临床意义[J]. 解剖学报, 2024, 55(1): 82-87.
[4]	杨洋史君李琨马渊张少杰侯二飞王超群陈杰王星李志军 . 切除不同范围钩突后颈椎椎间盘的有限元分析[J]. 解剖学报, 2024, 55(1): 88-97.
[5]	孙雷王星宇谢水华. 老年骨质疏松性胸腰椎压缩性骨折患者PKP术后再发骨折的风险分析及列线图预测模型的构建[J]. 解剖学报, 2024, 55(1): 98-104.
[6]	刘丽平朱梦妮徐慧 . 白细胞介素6对脂多糖诱导所致类子痫前期大鼠有核红细胞的影响 [J]. 解剖学报, 2023, 54(6): 722-729.
[7]	赵卫明李晓余国营王改平常翠芳 . 丝氨酸肽酶抑制因子Kazal型1对肝癌细胞增殖的影响及其机制 [J]. 解剖学报, 2023, 54(6): 695-702.
[8]	袁硕赵安全黄其日麦拉图吴海贺徐永胜齐岩松包呼日查 . 基于下肢全长CT分析胫骨平台后倾角和胫骨扭转角与复发性髌骨脱位的相关性 [J]. 解剖学报, 2023, 54(6): 703-709.
[9]	韩毅蔡力冯枭 . 脊柱骨质疏松性压缩性骨折经皮穿刺椎体成形后骨水泥渗漏风险分析及列线图预测模型的构建 [J]. 解剖学报, 2023, 54(6): 710-715.
[10]	王子善张兴华徐飞宇克莉郑连斌程瑜 . 云南布朗族、德昂族、佤族营养体格指数、肥胖状况及其高血压预警 [J]. 解剖学报, 2023, 54(6): 730-737.
[11]	席焕久李文慧 . 关于人种问题的讨论[J]. 解剖学报, 2023, 54(5): 605-614.
[12]	杜大鹏孙玉张敏王汉琴 . 切应力通过Pim1/Akt调节人脐静脉内皮细胞内皮型一氧化氮合酶Ser633和Ser1177位点磷酸化[J]. 解剖学报, 2023, 54(5): 546-552.
[13]	周春辉谢胜强王姜婷兰晓娟张剑宁赵虎林. 多模态电磁导航辅助新鲜尸头经鼻内镜的颅底解剖测量[J]. 解剖学报, 2023, 54(5): 560-566.
[14]	刘颜静史勇红. 基于FPFH-PointNet的术中膝关节软骨表面点云自动提取[J]. 解剖学报, 2023, 54(5): 553-559.
[15]	白芃李玮钟铧王展飞. 藏族正常成人头颅正中矢状面幕上和幕下面积的磁共振成像测量[J]. 解剖学报, 2023, 54(5): 567-574.